Apellis Pharmaceuticals, Inc. is a biopharmaceutical company based in the United States that focuses on developing novel therapeutic compounds to treat diseases with high unmet needs by targeting the complement system. With a medium-risk ESG score of 24.4, Apellis Pharmaceuticals is dedicated to sustainable and responsible business practices.